Acute Myelogenous Leukemia (AML) Clinical Trial
Official title:
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia
To determine the maximum tolerated dose of KW-2449 in people with acute myelogenous leukemia who are not candidates for approved therapy. As well, the study will determine the response rate to KW-2449.
Phase 1: To determine the maximum tolerated daily dose (MTDD) of KW 2449 when administered to subjects with AML who are not candidates for approved therapy. This was originally a Phase 1/Phase 2 study. However, a tolerable dose that had the potential for efficacy could not be identified in Phase 1. Therefore, Phase 2 was never conducted. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00528983 -
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
|
Phase 1 | |
| Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT01451437 -
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)
|
Phase 1 | |
| Completed |
NCT01885897 -
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
| Terminated |
NCT01873495 -
Omacetaxine for Consolidation and Maintenance
|
Phase 2 | |
| Terminated |
NCT03600909 -
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
|
Phase 2 | |
| Completed |
NCT00088543 -
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
|
N/A | |
| Active, not recruiting |
NCT02061800 -
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00943553 -
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
|
Phase 2 | |
| Terminated |
NCT01113502 -
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
|
Phase 1/Phase 2 | |
| Terminated |
NCT01050764 -
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
|
Phase 1/Phase 2 | |
| Terminated |
NCT00672152 -
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation
|
Phase 1 | |
| Recruiting |
NCT03260101 -
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
|
||
| Terminated |
NCT02200380 -
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
|
Phase 2 | |
| Active, not recruiting |
NCT02240537 -
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
|
Phase 1 | |
| Completed |
NCT01527838 -
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
|
Phase 1 | |
| Completed |
NCT01768845 -
Unrelated Umbilical Cord Blood (UBC)Transplantation
|
N/A | |
| Terminated |
NCT01265199 -
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
|
Phase 1 | |
| Completed |
NCT02793544 -
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 |